Evidence map›Paper›PMID 30374664›Full record

ReviewCurrent infectious disease reports2018

Risk of Dengue in Travelers: Implications for Dengue Vaccination.

Annelies Wilder-Smith

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current infectious disease reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Immunogenicity and safety of a tetravalent dengue vaccine in dengue-naïve adolescents in Mexico City.Revista panamericana de salud publica = Pan American journal of public health · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Annelies Wilder-SmithDepartment of Disease Control, London School of Hygiene and Tropical Medicine, Bloomsbury, UK. annelies.wilder-smith@lshtm.ac.uk.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewDengue is found in tropics and subtropics that are considered to be popular travel destinations. We set out to review the burden of dengue on international travelers. RECENT

findingsGeoSentinel, a global network of travel medicine providers, has seen an increasing trend of dengue in returning travelers over the past decades. In Southeast Asia, annual proportionate morbidity increased from 50 dengue cases per 1000 ill-returned travelers in non-epidemic years to an average of 159 cases per 1000 travelers during epidemic years. Dengue is the leading cause of fever in returning travelers, having overtaken malaria for travelers to Southeast Asia. Most dengue seroconversion studies in travelers report an attack rate of around 5% depending on duration of travel and destination. Dengue vaccination would be justified for travelers. The first licensed dengue vaccine CYD-TDV is only recommended in seropositive individuals. This review considers preventive measures including how best to use the first licensed dengue vaccine CYD-TDV.

Indexed as

DengueDengue vaccineGeoSentinelPersonal protectionSeroconversionTravelers

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.